© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Venclexta
Venclexta Provides Sustained Benefit for People With Leukemia
Venclexta, venetoclax
Venclexta 101
Leukemia 101
Red and white blood cells

Fixed-Duration Imbruvica-Venclexta Combo Benefits People With Chronic Lymphocytic Leukemia

For those with undetectable minimal residual disease, treatment discontinuation was as effective as staying on Imbruvica.

Venclexta Added to Standard Treatments Shows Promise for High-Risk Myeloid Blood Cancers

The drug targets cancer’s survival proteins, making them more vulnerable to treatments that cause cancer cells to self-destruct.
Red and white blood cells

FDA Grants Regular Approval of Venclexta Regimen For Untreated Acute Myeloid Leukemia

The regimen is approved for adults age 75 or older and those who cannot use intensive induction chemotherapy.

Targeted Combos Deal Double Blow Against Chronic Lymphocytic Leukemia

Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.
Catherine Wu, MD

Resistance to Targeted Leukemia Drug Lurks in Cells’ “Powerhouse”

In a recent study, Dana-Farber scientists and others uncovered a key part of why some patients eventually become resistant to Venclexta.
Red and white blood cells

Venclexta Improves Outcomes Among Those With Chronic Lymphocytic Leukemia

Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.

FDA Approves Venclexta for Certain Types of Leukemia and Lymphoma

Study found Venclexta plus Gazyva (obinutuzumab) delayed disease progression in previously untreated patients.

Targeted Treatment for Leukemia

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

Getting to the Root of Leukemia

Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
Human cells with acute myelocytic leukemia (AML) in the pericardial fluid, shown with an esterase stain at 400x

Drug Combo May Target Unique Metabolism of Leukemia Stem Cells

Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
Jennifer Woyach, MD

Imbruvica Bests Chemotherapy for Older People With Leukemia

Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
Red and white blood cells

CAR-T Therapy Shows Promise for Chronic Lymphocytic Leukemia

Customized cell therapy plus Imbruvica leads to high response rate.
Red and white blood cells

Targeted Therapy Combo Works Well for Chronic Lymphocytic Leukemia

Venclexta plus Gazyva reduces risk of disease progression or death.
Red and white blood cells

FDA Approves Venclexta for More Types of Leukemia

Approval was based on improves progression-free survival in the MURANO trial.
Human cells with acute myelocytic leukemia (AML) in the pericardial fluid, shown with an esterase stain at 400x

Drug Approvals Mark New Era in Treating Acute Leukemia in Adults

Oncologists are excited about the increased options available to patients, and about the promise of even more new therapies to come.
Red and white blood cells

Targeted Therapies Improve Outcomes for People With Chronic Lymphocytic Leukemia

Venclexta combination therapy clears leukemia in blood and bone marrow, recent studies show.
Advertisement
Science News
Blog: Food and Drug Administration (FDA)